$FRLF CB2 Insights Announces Industry’s First Fu
Post# of 517
(Total Views: 408)
Posted On: 12/16/2019 11:31:30 AM
$FRLF CB2 Insights Announces Industry’s First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly Freedom Leaf Inc.)
Press Release | 12/16/2019
Prospective trial marks first-of-its-kind study on the efficacy and safety of hemp-based CBD treatment focused on patients with anxiety
Announcement follows the passage of the 2018 US Farm Bill which legalized the mass production of hemp, a form of cannabis with lower THC levels than marijuana, across the United States
Partnership follows the request by the US Food and Drug Administration (FDA) for more clinical data to support the safety and efficacy of hemp-based CBD products within medical treatments
CB2 Insights previously announced partnership to serve as exclusive research technology platform for large UK-based medical cannabis pilot
TORONTO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced that it will begin a prospective trial with GL Brands (OTCQB: FRLF) through its U.S.-based hemp brand and key operating subsidiary, Green Lotus.
The study will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules when looking to treat anxiety. (cont'd)
https://www.otcmarkets.com/stock/FRLF/news/CB...?id=249358
Press Release | 12/16/2019
Prospective trial marks first-of-its-kind study on the efficacy and safety of hemp-based CBD treatment focused on patients with anxiety
Announcement follows the passage of the 2018 US Farm Bill which legalized the mass production of hemp, a form of cannabis with lower THC levels than marijuana, across the United States
Partnership follows the request by the US Food and Drug Administration (FDA) for more clinical data to support the safety and efficacy of hemp-based CBD products within medical treatments
CB2 Insights previously announced partnership to serve as exclusive research technology platform for large UK-based medical cannabis pilot
TORONTO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced that it will begin a prospective trial with GL Brands (OTCQB: FRLF) through its U.S.-based hemp brand and key operating subsidiary, Green Lotus.
The study will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules when looking to treat anxiety. (cont'd)
https://www.otcmarkets.com/stock/FRLF/news/CB...?id=249358
(1)
(0)GL Brands Inc. (GRLB) Stock Research Links
$MJ